
Aduro Announces Readiness of Scaled-up Continuous Flow Plastic Reactor for Customer Trials
SARNIA, Ontario, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (CSE: ACT) (OTCQB: ACTHF) (FSE: 9D50), a Canadian developer of patented water-based technologies to chemically recycle plastics and transform heavy crude and renewable oils into new-era resources and higher-value fuels, announces it is entering final stages of completion of its pilot-scale HydrochemolyticTM continuous flow plastic (“R2 Plastic”) reactor.
The R2 Plastic unit is in the final assembly phase, plans for testing, commissioning, and certification are finalised and expected to be complete by mid November 2022.
The R2 Plastic unit is the Company’s customer engagement unit and is designed to handle various plastic feedstocks such as polyethylene, polypropylene, and polystyrene as single stream materials, followed by a mixture of these feedstock streams. The R2 Plastic will also be used to evaluate the impact of materials found in multilayer plastics, such as paper, paper board, polymeric materials, metalized layers, or aluminum foil, effectively advancing Aduro’s plans of processing higher contaminated materials which are currently rejected by existing technologies. This is important data that will support the Company’s established scale-up and optimization program for the pre-commercial pilot: R3 Plastic.
The R3 Plastic unit is a continuous flow reactor with a targeted throughput of 2,000 kg/day. Preliminary design and materials and component scoping of the unit have been started with a plan to commission the unit before the end of 2023. Aduro is also working on measures to secure and maximise non-dilutive sources of funding to support its roadmap to commercialisation.
While the R2 Plastic unit is the key tool in the Company’s approach to building a pipeline of commercial projects, the R3 Plastic unit is the Company’s pre-commercial unit and the next scale-up step before finalising the plans for a commercial unit design and workflow. With R2 Plastic, the Company will engage with potential customers through product sample analysis and characterization, data, material exchange and technology demonstrations with the aim of facilitating business discussions and building a commercial pipeline.
“My full appreciation and thanks for the Aduro team that is working tirelessly to complete the significant milestones ahead of us. The commissioning of the R2 Plastic unit is a major building block towards commercialization and is part of several significant projects the company has undertaken over the last year. Among these are completing the expanded and upgraded laboratory facilities, commissioning of the R2 Bitumen unit and our Flash Drum. With the planned commissioning of R2 Plastic and the commencement of the planned customer trial program, the team at Aduro is very excited to be approaching this pivotal stage for the Company,” commented Ofer Vicus, Chief Executive Officer of Aduro.
About Aduro Clean Technologies
Aduro Clean Technologies is a developer of patented water-based technologies to chemically recycle waste plastics; convert heavy crude and bitumen into lighter, more valuable oil; and transform renewable oils into higher-value fuels or renewable chemicals. The Company’s Hydrochemolytic™ technology activates unique properties of water in a chemistry platform that operates at relatively low temperatures and cost, a game-changing approach that converts low-value feedstocks into 21st-century resources.
For further information, please contact:
Ofer Vicus, CEO
ovicus@adurocleantech.com
Abe Dyck, Investor Relations
ir@adurocleantech.com
+1 604-362-7011
Investor Cubed Inc.
Neil Simon, CEO
nsimon@investor3.ca
+ 1 647 258 3310
Forward-Looking Statements
This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future, are forward-looking statements. The forward-looking statements reflect management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Important factors that could cause actual results to differ materially from the Company’s expectations include adverse market conditions and other factors beyond the control of the parties. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.
The CSE has not reviewed, approved, or disapproved the content of this news release.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Veteran MedTech leader and hospital group CEO joins CMR Surgical as global Chief Commercial Officer11.12.2023 08:00:00 CET | Press release
Veteran MedTech leader and hospital group CEO joins CMR Surgical as global Chief Commercial Officer Massimiliano Colella joins as global Chief Commercial Officer leading CMR Surgical’s commercial and marketing operations to bring Versius to more hospitals around the worldMassimiliano joins CMR at a time of continued expansion as the second largest soft tissue surgical robotics company, with more than 140 Versius installations and more than 15,000 surgical procedures completedFollowing the recent $165 million financing round, CMR continues to pursue its expansion plans and new market regulatory approvals to bring Versius to more hospitals and patients around the world CAMBRIDGE, UK – Monday 11 December 2023, 07:00 (GMT). CMR Surgical (“CMR” or “the Company”), the global surgical robotics business, today announces that Massimiliano Colella has joined the Company as global Chief Commercial Officer. In his role, Massimiliano will oversee CMR’s commercial and marketing operations. Massimili
Azerion simplifies loan structures between Azerion and Principion11.12.2023 07:30:00 CET | Press release
Amsterdam, 11 December 2023 – Azerion Group N.V. ("Azerion") announces that it has today entered into an agreement with Principion Holding B.V. ("Principion") to simplify Azerion's loan structure by settling several loans outstanding between Azerion and Principion (the "Loan Settlement"). The objectives of the Loan Settlement are to simplify Azerion’s capital structure by setting off mutually outstanding unsecured liabilities, whilst at the same time providing Azerion with security against remaining balances. The Loan Settlement also provides Azerion the ability to use any ordinary shares in the capital of Azerion (the "Shares") to be acquired through the Loan Settlement mechanism for value creating purposes for all shareholders without the issuance of new Shares. The Loan Settlement has been approved by Azerion's management board and supervisory board. As at the date of this press release, the aggregate amount due and outstanding under the loans provided by (i) Principion to Azerion i
Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio®11.12.2023 07:30:00 CET | Press release
Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio® Data presented at the DGSM Conference in Berlin by Dr. Christian Plettenberg on December 8, 2023 Results showed an average AHI decrease of 73% Mont-Saint-Guibert, Belgium – December 11, 2023, 7:30am CET / 1:30am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced data from a real-world case series evaluating treatment of three complete concentric collapse (CCC) patients with the Genio® hypoglossal nerve stimulation system. The investigator-sponsored case series was presented by Dr. Christian Plettenberg from the Universitätsklinikum Düsseldorf on December 8, 2023. Results showed an average apnea-hypopnea index (AHI) decrease of 73% and Epworth Sleepiness Scale (ESS) decrease of 58%. There were no imp
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis11.12.2023 07:15:00 CET | Press release
Allschwil, Switzerland, December 11, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its license partner Astellas Pharma US, Inc. (“Astellas”) received the approval of Cresemba® (isavuconazole) for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients by the US Food and Drug Administration (FDA). Cresemba for injection is approved for adults and now for pediatric patients 1 year of age and older. Cresemba capsules are approved for adults and now for pediatric patients 6 years of age and older, who weigh 16 kilograms and greater. Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “We congratulate Astellas on the approval of Cresemba for the use in children who suffer from invasive aspergillosis or mucormycosis. These severe mold infections primarily affect children suffering
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)11.12.2023 07:15:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1; the safety profile of iptacopan was consistent with previously reported data1-3 C3 glomerulopathy (C3G) is an ultra-rare complement-mediated kidney disease, with approximately 50% of patients progressing to kidney failure within 10 years of diagnosis4-7; currently no treatments address the underlying cause of C3G7-9 Novartis plans to review results with global health authorities to enable potential submissions in 2024; data will be submitted for presentation at an upcoming medical meeting Iptacopan demonstrated positive Phase III results in IgA nephropathy (IgAN) at the interim analysis and a late-stage development program is ongoing across four investigational indications10-14 Basel, December 11, 2023 — Novartis today announced positive topline results from the six-month, double-blind period